Seddek Ahmed, Annamalai Thirunavukkarasu, Tse-Dinh Yuk-Ching
Department of Chemistry and Biochemistry, Florida International University, Miami, FL 33199, USA.
Biomolecular Sciences Institute, Florida International University, Miami, FL 33199, USA.
Microorganisms. 2021 Jan 1;9(1):86. doi: 10.3390/microorganisms9010086.
Infectious diseases are one of the main causes of death all over the world, with antimicrobial resistance presenting a great challenge. New antibiotics need to be developed to provide therapeutic treatment options, requiring novel drug targets to be identified and pursued. DNA topoisomerases control the topology of DNA via DNA cleavage-rejoining coupled to DNA strand passage. The change in DNA topological features must be controlled in vital processes including DNA replication, transcription, and DNA repair. Type IIA topoisomerases are well established targets for antibiotics. In this review, type IA topoisomerases in bacteria are discussed as potential targets for new antibiotics. In certain bacterial pathogens, topoisomerase I is the only type IA topoisomerase present, which makes it a valuable antibiotic target. This review will summarize recent attempts that have been made to identify inhibitors of bacterial topoisomerase I as potential leads for antibiotics and use of these inhibitors as molecular probes in cellular studies. Crystal structures of inhibitor-enzyme complexes and more in-depth knowledge of their mechanisms of actions will help to establish the structure-activity relationship of potential drug leads and develop potent and selective therapeutics that can aid in combating the drug resistant bacterial infections that threaten public health.
传染病是全球主要死因之一,抗菌药物耐药性构成了巨大挑战。需要开发新的抗生素以提供治疗选择,这就要求识别并寻找新的药物靶点。DNA拓扑异构酶通过与DNA链通过偶联的DNA切割-重新连接来控制DNA的拓扑结构。在包括DNA复制、转录和DNA修复在内的重要过程中,必须控制DNA拓扑特征的变化。IIA型拓扑异构酶是公认的抗生素作用靶点。在本综述中,细菌中的IA型拓扑异构酶被作为新抗生素的潜在靶点进行讨论。在某些细菌病原体中,拓扑异构酶I是唯一存在的IA型拓扑异构酶,这使其成为有价值的抗生素靶点。本综述将总结近期为鉴定细菌拓扑异构酶I抑制剂作为抗生素潜在先导物所做的尝试,以及这些抑制剂在细胞研究中作为分子探针的应用。抑制剂-酶复合物的晶体结构及其作用机制的更深入了解将有助于建立潜在药物先导物的构效关系,并开发出有效的选择性治疗药物,以帮助对抗威胁公众健康的耐药细菌感染。